Last reviewed · How we verify
Robitussin Extra Strength Chest Congestion
Robitussin Extra Strength Chest Congestion is a Small molecule drug developed by Reckitt Benckiser Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Robitussin Extra Strength Chest Congestion |
|---|---|
| Sponsor | Reckitt Benckiser Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Robitussin Extra Strength Chest Congestion CI brief — competitive landscape report
- Robitussin Extra Strength Chest Congestion updates RSS · CI watch RSS
- Reckitt Benckiser Inc. portfolio CI
Frequently asked questions about Robitussin Extra Strength Chest Congestion
What is Robitussin Extra Strength Chest Congestion?
Robitussin Extra Strength Chest Congestion is a Small molecule drug developed by Reckitt Benckiser Inc..
Who makes Robitussin Extra Strength Chest Congestion?
Robitussin Extra Strength Chest Congestion is developed by Reckitt Benckiser Inc. (see full Reckitt Benckiser Inc. pipeline at /company/reckitt-benckiser-inc).
What development phase is Robitussin Extra Strength Chest Congestion in?
Robitussin Extra Strength Chest Congestion is in Phase 1.